1025066-16-3

Basic information

• Product Name: 3-BroMo-6-chloro-7-MethyliMidazo[1,2-b]pyridazine
• Synonyms: 3-BroMo-6-chloro-7-MethyliMidazo[1,2-b]pyridazine;3--bromo-6-chloro-7-methylImidazo[1,2-b]pyridazine（WS201711）
• CAS NO: 1025066-16-3
• Molecular Formula: C7H5BrClN3
• Molecular Weight: 246.4917
• Mol File: 1025066-16-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-BroMo-6-chloro-7-MethyliMidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BroMo-6-chloro-7-MethyliMidazo[1,2-b]pyridazine(1025066-16-3)
• EPA Substance Registry System: 3-BroMo-6-chloro-7-MethyliMidazo[1,2-b]pyridazine(1025066-16-3)

Safety Data

• Hazardous Substances Data: 1025066-16-3(Hazardous Substances Data)

Upstream product

• 107-20-0 2-chloroethanal 
• 66346-87-0 6-chloro-5-methylpyridazin-3-amine 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 17412-19-0 6-chloro-7-methylimidazo[1,2-b]pyridazine 

Relevant articles and documents

IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF

Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES

The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS

New imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).